26.12.2012 Views

IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC ...

IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC ...

IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Table 3. DNA adduct formation in Chinese herb nephropathy (CHN) patients<br />

Details of study DNA binding Reference<br />

Detection of AA-specific DNA adducts in renal tissue from 5 female patients<br />

with CHN from Belgium by 32 P-postlabelling. DNA was obtained from<br />

cortical or cortico-medullary tissue. The patients had taken pills containing<br />

Chinese herbs for 13–23 months. The adduct chromatographically<br />

indistinguishable from dA-AAI was detectable up to 27 months after<br />

termination of the regimen.<br />

Detection of AA-specific DNA adducts in the kidneys and one ureter from 6<br />

female patients with CHN from Belgium by 32 P-postlabelling (five cases<br />

were from Schmeiser et al., 1996). Three AA-specific adducts<br />

chromatographically indistinguishable from dA-AAI, dG-AAI and dA-AAII<br />

were detectable up to 44 months after termination of the regimen.<br />

Detection of AA-specific DNA adducts in the kidneys of CHN patients<br />

(37 female and one male), and in 17 ureters from 11 of these patients from<br />

Belgium by 32 P-postlabelling. Among these patients were 18 cases of<br />

urothelial carcinoma. Data were related to cumulative doses of compounds<br />

in the weight-reducing pills on the basis of all prescriptions made during the<br />

period of exposure (1990–92). The cumulative dose of aristolochia was a<br />

significant risk factor for developing urothelial carcinoma. The kidneys and<br />

ureters from the CHN patients had the same pattern of adducts consisting of<br />

dA-AAI, dG-AAI and dA-AAII. The major adduct dA-AAI was detectable<br />

up to 89 months after discontinuation of use of the weight-reducing pills. No<br />

statistically significant difference was observed between mean levels of dA-<br />

AAI DNA adducts determined in renal tissue samples from patients who had<br />

developed urothelial carcinoma and those from tumour-free patients.<br />

Detection of AA-specific DNA adducts in the kidneys from 2 new female<br />

CHN patients from the Belgian cohort by 32 P-postlabelling.<br />

dA-AAI: 0.7–5.3/10 7 nucleotides Schmeiser<br />

et al. (1996)<br />

dA-AAI: 0.7–5.3/10 7 nucleotides<br />

dG-AAI: 0.02–0.12/10 7 nucleotides<br />

dA-AAII: 0.06–0.24/10 7 nucleotides<br />

In the kidneys: dA-AAI: 1.2–165/10 9 nucleotides<br />

dG-AAI: 0.4–8.2/10 9 nucleotides<br />

dA-AAII: 0.6–6.8/10 9 nucleotides<br />

In the ureters: dA-AAI: 2.2–34/10 9 nucleotides<br />

Bieler et al.<br />

(1997)<br />

Nortier et al.<br />

(2000)<br />

2.9–5.0/10 8 nucleotides Arlt et al.<br />

(2001a)<br />

SOME TRADITI<strong>ON</strong>AL HERBAL MEDICINES 97

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!